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Abstract 
Pituitary tumours are a common pathology affecting 15–20% of the population. Only about 1‰ of adenomas are clinically manifested; 
among them, about two/thirds are hormonally active, most often secreting prolactin or growth hormone. Pituitary tumours are mainly 
an isolated pathology, without any genetic background. However, the latest studies pay special attention to the possibility of developing 
an adenoma as a result of genetic mutation. Among pituitary adenomas, the leading group of genetically determined lesions is related to 
a mutation in AIP or MEN1, followed by PRKAR1A, GRP101, DICER, and SDHx. The genetic basis of these pituitary tumours is related to 
positive family history, young age of the patient, aggressive clinical process, and resistance to treatment. Pituitary tumours occur in over 
40% of patients with MEN1 syndrome — often in women, they are more than 1 cm in diameter, and secrete prolactin. They are usually 
diagnosed in the fourth decade of life and show a worse response to pharmacotherapy than sporadic ones. Confirmation of the genetic 
background of the pituitary tumour implies measurable implications; it might help to direct the diagnosis in patients’ family members, 
partially predict the development of the disease, and, above all, extend patients’ life expectancy. (Endokrynol Pol 2019; 70 (5): 445–452)
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General characteristics of pituitary tumours
In the times of common availability of imaging studies 
of the central nervous system, the number of lesions de-
tected in the sella turcica is increasing; the most commonly 
described pathologies are pituitary adenomas. Organic 
changes found in the pituitary gland constitute 10-15% 
of all intracranial tumours and are the reason for every 
fourth neurosurgical intervention in the brain area [1, 2]. 
Pituitary microadenomas are found in imaging and au-
topsy studies in 14.4% and 22.5% of patients, respectively 
[1], while the incidence increases with age (up to 30% in 
the sixth decade of life) [3]. Clinically significant tumours 
account for 1 in 1000 cases in the general population [4, 
5]. Most of them are sporadic, but the range of genetically 
determined cases is estimated to be from 5% to as much 
as 40% [6]. Mutations more often relate to somatic than 
gender line cells, with the possibility of mosaicism [6, 7]. 
Genetically related pituitary tumours are most often the 
result of mutations in the AIP, MEN1, CDKN1B, GPR101, 
PRKAR1A, SDHx, NF1, and DICER genes.
MEN1 syndrome
The first literature reports about the MEN1 syndrome 
date back to the 1950s, when Underdahl published 
a review of cases of multiple parathyroid adenomas in 
patients with acromegaly [8–10]. Wermer is considered 
to be the author of the genetic model of inheritance; 
in 1960 he described a case of familial coexistence of 
the above polyendocrinopathy, raising the suspicion 
of autosomal-dominant inheritance with high pen-
etrance [11]. Identification of mutations in the MEN1 
gene located on chromosome 11q13 was described in 
1997 [12]. At the beginning of the twenty-first century, 
Thakker published the series of papers in which MEN1 
syndrome is characterised as a genetically conditioned 
occurrence of endocrine tumours (autosomal-dominant 
inheritance with high penetrance), particularly pitu-
itary, parathyroid, and pancreatic islet cells. In addition, 
carcinoids, adrenocorticotropic tumours, facial angiofi-
bromas, lipomas, and fibromas may also be present in 
the syndrome [13, 14] (Fig. 1).
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de  novo mutations that will be inherited by the next 
generation in an autosomal-dominant manner [20]. The 
fact of inheritance in an autosomal-dominant manner 
with high penetrance results in a 50% risk of transfer-
ring the genetic variant to the offspring and a 90% 
risk of developing the syndrome in people who have 
inherited the variant. Expert groups have made efforts 
to establish recommendations systematising current 
knowledge and the diagnostic and control process [13]. 
Analysing the unselected population of patients 
with pituitary tumours, coexistence of primary hyper-
parathyroidism was found in only 4.8% of patients. The 
MEN1 mutation was found in 14.3% of patients with 
prolactin tumours. In the majority of patients, the pi-
tuitary tumour was diagnosed several years before the 
diagnosis of hyperparathyroidism. It should be noted 
that some pituitary tumours were considered sporadic 
despite the occurrence of other endocrine disorders 
typical for MEN, so MEN1 syndrome may remain un-
recognised in some cases [15].
Diagnosis of the MEN1 syndrome results in sig-
nificant health effects — for the patients and for their 
relatives [20–22]. The risk of developing a syndrome in 
each first-degree relative of a patient with genetically 
conditioned MEN1 syndrome is 50% [20]. Thus, it is 
necessary to conduct a complete diagnostic process, 
including firstly the confirmation of the mutation and 
then an active search for typical components of the syn-
Epidemiology
Based on random post-mortem examinations, the 
prevalence of MEN1 is estimated to be 0.25%, an aver-
age of 1:30,000 people. About 10% of genetic changes 
are de  novo variants, which are the basis of sporadic 
disease occurrence; the remaining genetic variants oc-
cur in families [13]. MEN1 syndrome occurs in 1–18% of 
patients with primary hyperparathyroidism, in 16–38% 
of patients with gastrinoma, and in fewer than 3% of 
patients with pituitary tumours [13, 15]. The disease 
occurs in all age groups; cases of the presentation of 
the syndrome have been described in patients between 
five and 81 years of age [16, 17]. MEN1 is characterised 
by high penetrance — clinical and biochemical mani-
festations occur in 80–100% of patients [18]; whereas, 
in over 98% of cases symptoms will occur up to the age 
of 50 years [13, 16, 19].
Diagnostics of MEN1 syndrome
MEN1 syndrome is usually an autosomal-dominant 
disorder, but it is also possible for it to occur in sporadic 
cases, i.e. without a positive family history. However, 
one should remember the limitations resulting from 
the inability to perform diagnostics in the proband’s 
family (lack of consent for genetic testing, death, late 
manifestation in the parents [18]), which may result in 
an unrecognised familial form of the disease. Ultimately, 

























Figure 1. Tumours in MEN1 syndrome in 220 patients. The graph is a schematic presentation of the distribution of 384 tumours found 
in 220 patients with MEN1 syndrome. The percentages of patients with parathyroid, pituitary, pancreatic, and coexisting tumours 
are described in the individual fields. For example, 37.7% (25.9% + 11.8%) of patients had a comorbid pancreatic and parathyroid 
tumour, while only 2.3% had an isolated pancreatic tumour. Parathyroid tumours are the most common pathology in MEN1 syndrome 
(95%), followed by pancreatic (40.5%) and pituitary tumours (29.5%). Others, listed on the left, constitute a small percentage of 
tumours in MEN1 syndrome. GAS — gastrinoma; INS — insulinoma; GCG — glucagonoma; NFT — non-secretory tumours; 
PRL — prolactinoma; GH — somatotropinoma; ACTH — adrenocorticotropinoma [14]. Reprinted with the consent of Prof. Thakker 
and Oxford University Press
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drome [16]. Clinical evaluation with biochemical and 
radiological tests is performed to detect the tumours.
Diagnosis of MEN1 syndrome is established based 
on the following criteria:
 — clinical evidence, i.e. patients with at least two tu-
mours typical of MEN1 syndrome;
 — family premises, i.e. patients with one tumour 
typical of MEN1 and one first-degree relative with 
a confirmed MEN1 mutation;
 — asymptomatic carriers, i.e. people without clinical 
and/or biochemical symptoms, in cases with a con-
firmed MEN1 mutation [14, 16, 20].
Detection of MEN1-related tumours
Suspicion of MEN1 mutation is associated with the 
presence of constellations of endocrine disorders. Ge-
netic diagnosis should be carried out in the following 
cases: (a) in any patient with a positive family history 
of neuroendocrine tumours of the pancreas, pituitary, 
or parathyroid gland and with familial occurrence 
of endocrine system disorders; (b) in patients with 
Zollinger-Ellison syndrome; (c) in young patients with 
hormonally active pituitary tumours; (d) in people 
with multiple pancreatic tumours/neoplasms; (e) in 
people with hyperparathyroidism and multiple para-
thyroid gland adenomas /hyperparathyroidism, in 
particular up to 45 years of age [23]; and (f) in people 
with a pituitary tumour and hypercalcaemia or other 
endocrinopathy [14, 24]. 
According to the recommendations of the European 
Society of Endocrinology published in 2018, genetic 
tests (searching for pathogenic variants of MEN1 and/or 
AIP) should be carried out among patients with aggres-
sive pituitary tumours. The test should be determined 
taking into account the age of the patient at the time of 
diagnosis and presence of positive family history of pi-
tuitary or endocrine system neoplasms. The guidelines 
indicate the need to look for markers that allow clear 
differentiation between aggressive and non-aggressive 
tumours [25].
The identification of a pathogenic variant in the 
MEN1 gene is tantamount to the need to carry out 
diagnostics to exclude/confirm the components of the 
syndrome [16]. The first stage of diagnosis is to select 
a population of potential carriers of the pathogenic vari-
ant of the MEN1 gene (described above) and perform 
genetic diagnostics. If the presence of the mutant gene 
is confirmed, genetic counselling should be conducted 
also among first-degree relatives of the proband (to 
determine whether the mutation concerns the germline 
or has appeared de novo in the proband), in addition to 
the clinical, biochemical, and radiological evaluation of 
the carrier. The finding of a germinal mutation results 
in periodic tests of asymptomatic carriers [14].
MEN1 gene testing should include sequence analy-
sis as well as analysis of large deletions within the 
gene. The deletion analysis is usually performed in 
the second line if no pathogenic changes are detected 
in the MEN1 gene sequence in a given patient. The 
decision to extend the scope of genetic testing should 
be made on the basis of specific clinical premises. In 
patients with a negative result of MEN1 mutation 
screening, other genetic syndromes with hyperpara-
thyroidism should be considered: CDC73 mutations 
associated with parathyroid gland hyperactivity 
syndrome (PTH-JT) or calcium receptor (CASR) muta-
tions causing familial hypocalciuric hypercalcaemia 
(FBHH). Genetic diagnostics for pituitary tumours 
can be extended to include pathogenic variants in the 
CDKN1B and AIP genes.
In a symptomatic person (e.g. with hypercalcaemia) 
with the MEN1 syndrome diagnosed in their family, 
annual clinical, biochemical, and radiological evalua-
tion should be carried out even if no pathogenic MEN1 
variant has been detected in the genetic test. In asymp-
tomatic first-degree relatives of a person with MEN1 
syndrome, in which no pathogenic MEN1 variant could 
be confirmed, a targeted clinical and biochemical evalu-
ation is recommended [14]. This approach is justified 
in view of a possibly different clinical presentation of 
MEN1 syndrome even among members of one family 
[26]. MEN1 syndrome occurs in 90% of cases on the 
basis of a pathogenic variant occurring in the family, 
with a penetrance of up to 100% [18].
The screening scheme discussed above includes 
regular monitoring of calcium, parathyroid hormone 
(PTH), prolactin (PRL), chromogranin A (CgA), and 
fasting glucose levels and pituitary gland MRI and 
MRI /CT of the abdominal cavity and chest at a specific 
frequency (Fig. 2) [14]. The  earliest (87%) and most 
frequently (95%) found abnormality is hypercalcaemia 
due to primary hyperparathyroidism, which is followed 
by tumours of the pancreas (41%) and pituitary gland 
(30%) [13, 14, 16].
Prospective analyses have shown that biochemical 
changes might precede the clinical manifestation of the 
disease by about 10 years [18]. For the early detection 
of a pituitary tumour in a person with a family his-
tory of MEN1 syndrome, measurement of prolactin 
and IGF-1 concentration and performing an imaging 
examination of the sella turcica are recommended. Ac-
cording to the Endocrine Society guidelines published 
in 2012, diagnostics should be started at the age of five 
years: hormone measurements should be performed 
annually, and MRI should be performed every three 
years [14]. Subsequent studies support this statement 
[27], but shortening the interval between MRI exami-
nations to two years [28]. In recent years, in light of 
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such frequent MRI scans, the safety of the examination 
without the use of gadolinium enhancement has been 
emphasised [29, 30].
Manifestation and prognosis of MEN1 syndrome
In most cases (83%), the clinical manifestation of the 
syndrome occurs after the age of 21 years of age; how-
ever, various components of MEN1 syndrome may oc-
cur in individuals younger than 10 years, in as many as 
14% of patients [31]. No predilection has been described 
for age among aggressive tumours [31]. A multicentre 
analysis by Goudet et al. of the causes of death among 
patients with MEN1 syndrome showed that about 70% 
of them die as a result of diseases constituting the com-
ponents of the syndrome. It has been established that 
gastrinoma (RR 1.9), non-secreting pancreatic tumour 
(RR 3.4) and glucagon, and somatostatin and VIP-se-
creting tumours (RR 4.3) are associated with higher risk 
of death. Diagnosis of an insulinoma, pituitary tumour 
or bronchial tumour did not affect the prognosis. Lower 
risk of death was observed in females, in cases of fa-
milial MEN1 syndrome and in cases diagnosed after 
1980 [32]. The above-mentioned analysis emphasised 
the significant reduction in the number of deaths due 
to peptic ulcer observed since 1990, which is probably 
a result of the introduction of the use of proton pump 
inhibitors [33].
The treatment principles for individual tumours do 
not deviate from the standards developed for tumours 
unrelated to MEN1 syndrome, but the outcomes of 
treatment are not as favourable. Worse response is con-
nected with a higher incidence of multiple tumours, 
which significantly limits the effectiveness of surgical 
procedures [14]. An example may be the long-term ef-
fects of surgical treatment of gastrinomas, which occur 
in MEN1 syndrome as multifocal submucosal tumours 
Figure 2. Recommended diagnostic procedures and care for patients with suspected MEN1 syndrome [13]. Description in the text. 
Reprinted with permission of Oxford University Press. CA2+ — calcium ion; PTH — parathyroid hormone; PRL — prolactin; 
IGF-1 — insulina-like growth factor 1; CgA — chromogranin A; MRI — magnetic resonance imaging; CT — computed tomography; 























































within the duodenum — in a five-year follow-up after 
surgery, no recurrence was observed in only 5% of pa-
tients with a MEN1 mutation, while in the group without 
MEN1 mutation this was true in 40% of cases [34, 35].
In the case of multiple parathyroid adenomas, 
characteristic for MEN1 syndrome, subtotal parathy-
roidectomy results in persistent/recurrent hypercalcae-
mia within 10 years in 20-60% of patients with MEN1 
syndrome, compared to 4% in the group without 
MEN1 mutation [16, 36, 37]. The dissemination of 
neuroendocrine tumours is also more often observed 
in patients with MEN1 syndrome: insulin tumours in 
the course of MEN1 syndrome show the presence of 
metastatic lesions in almost 50% of cases (in sporadic 
tumours this is approximately 10%) [38].
Pituitary tumours in MEN1 syndrome
The presence of a pituitary tumour is found in 15–50% 
of patients with MEN1 syndrome [9, 13]. It is rarely the 
first manifestation of the syndrome — only in about 
15% of patients with the sporadic form of the syndrome 
(range from 10% to 25%) [39] and less than 10% in the 
familial form [16].
Pituitary tumours related to MEN1 mutation are 
larger, more aggressive, and resistant to conventional 
therapy. 85% of tumours associated with the syndrome 
are macroadenomas, while among sporadic cases 42% 
were lesions above 1 cm [39]. The relationship between 
tumour invasiveness (grade III and IV according to the 
Vezina-Hardy grades classification, Tab. I) and the pres-
ence of a MEN1 mutation is not unambiguous: sporadic 
tumours were more frequently observed in grades I and 
III, while grades II and IV were dominated by tumours 
associated with the MEN1 syndrome [39].
Clinical manifestation is typical for particular types 
of hypersecretion; in the case of the most common 
prolactin-secreting tumour, there are galactorrhoea, 
menstrual disorders (including secondary absence of 
menstruation), infertility, and libido disorders. Clini-
cal symptoms (headaches or defects in the visual field) 
are more often associated with MEN1-related tumours 
(14% to 29%) [39]. MEN1-related pituitary tumours oc-
cur more frequently in women than in men, similarly 
as in the case of pituitary tumours in general [39, 41].
Pituitary tumours associated with MEN1 syndrome 
occur in younger age groups compared to sporadic 
tumours [9, 13]. In Carty’s studies, the average age of 
diagnosis was 39.8 years (from 18 to 73 years). Based on 
a prospective analysis, penetrance was estimated at 28% 
at the age of 30 years, 48% at the age of 50 years, and 
64% at the age of 70 years [42]. The majority of pituitary 
tumours are hormonally active: about 60% secrete pro-
lactin, 25% growth hormone, 5% adrenocorticotropic 
hormone; the rest are non-secretory tumours [13, 43]. 
The percentage of hormonally active MEN1-related 
pituitary tumours is not significantly different than the 
percentage in sporadic tumours [41], but MEN1-related 
tumours more often secrete more than one hormone 
(39% of tumours) [9, 41]. This may be the reason for dis-
crepancies in the distribution of hypersecretion shown 
in the literature [41]. The most common type of mixed 
tumour is prolactin and adrenocorticotropin-secreting 
tumour (PRL — ACTH), which is extremely rare among 
tumours without mutations in the MEN1 gene [41].
In addition to mixed tumours, there are also 
multiple tumours observed which are clinically dif-
ficult to distinguish from the pituitary hyperplasia 
described in autopsy studies of pituitaries of patients 
with MEN1 mutations [41]. However, no nuclear or 
cytoplasmic features that characterise MEN1-related 
tumours have been established except for increased 
immunoreactivity of S100 protein antibodies [41]. There 
are no histopathological features to distinguish pituitary 
tissue derived from sporadic tumours from familial or 
MEN1-related tumours [44]. Hyperplasia may result 
from the ectopic production of liberins. The literature 
reviews cases of patients with MEN1 syndrome with 
clinical and biochemical indicators of acromegaly with-
out pituitary lesion (confirmed in the autopsy study). 
The causes of growth hormone excess were neuroen-
docrine pancreatic tumours secreting somatoliberin [41, 
45–47]. There are also other examples of ectopic GHRH 
secretion [48, 49].
Despite the tendency to be more invasive with 
worse response to treatment and larger size, there 
was no higher incidence of malignant transformation 
compared to sporadic tumours. So far, three cases of 
pituitary cancer have been described in patients with 
pituitary tumour associated with a pathogenic variant 
of MEN1. The first concerned a woman with sporadic 
MEN1 syndrome and a gonadotropin-secreting tumour 
Table I. The classification of Vezina-Hardy-Wilson is based on 
anatomical and radiological correlation of pituitary tumours. 
Distinguishes five stages of tumour development based on size 
and expansion beyond the sella turcica
Grade I Microadenoma — a pituitary tumour, size less than 10 mm
Grade II Macroadenomas — tumour larger than 10 mm, but not destroying the bone structure of the sella turcica
Grade III Tumours exhibiting local invasiveness, enlargement of the sella turcica, and erosion of bone wall
Grade IV Invasive tumours causing extensive destruction of the bony walls of the sella turcica
Grade V The tumour of the sella turcica with the presence of blood-borne or cerebrospinal fluid metastases [40]
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[50], the second — a man with a tumour secreting pro-
lactin and familial MEN1 syndrome [51], and the third 
— a man with a tumour producing thyroid-stimulating 
hormone in the course of sporadic MEN1 syndrome 
[52]. To date, no definite markers have been found that 
allow for early identification of a malignant tumour. The 
diagnosis of cancer is based on the presence of local (in 
the central nervous system) or distant metastases [25].
The therapy of pituitary tumours in patients with 
a confirmed mutation in the MEN1 gene does not 
deviate from routine management. It is based on the 
use of standard therapy, i.e. cabergoline/bromocriptine 
in the case of a prolactin tumour and neurosurgical 
treatment preceded by the preparatory use of lanreo-
tide/octreotide in  somatotropic tumours. Depending on 
the clinical situation, reoperation and/or radiotherapy 
for residual tumour mass is performed [3]. In the case 
of biologically aggressive tumours (the presence of at 
least one among: Ki-67 ≥ 3% and/or increased mitotic 
value > 2 and/or p53 protein expression), temozolomide 
therapy is used [25, 53].
MEN1-related pituitary tumours show a worse 
response to the above therapies measured by nor-
malisation of pituitary hormone concentrations, which 
was achieved in 42% of patients with MEN1-related 
tumours compared to 90% efficacy in the population 
of patients with sporadic tumours [39]. In addition, the 
analysis of treatment effectiveness of the most common 
type of hypersecretion — prolactinoma — showed 
normalisation of prolactin concentration in only 44% 
of patients. The above data suggest that patients with 
pituitary tumours as a result of a mutation in the MEN1 
gene are a group of patients more frequently undergo-
ing neurosurgical treatment due to the lack of response 
to pharmacological treatment [14].
The absence of such a correlation was demonstrated 
by Danish researchers. Among 323 people with MEN1, 
123 (38.1%) had a pituitary tumour with an average size 
of 8.9 ± 0.7 mm; in subsequent imaging of microadeno-
mas, they did not show a significant increase in tumour 
size. The response to treatment in the whole group did 
not significantly differ from the general population: 
efficacy was estimated at > 90% [54].
The decision regarding surgical treatment of a pro-
lactin-secreting tumour is usually made after pharma-
cological treatment. According to the guidelines of the 
Endocrine Society, indications for surgical treatment of 
prolactinoma are: 1) pressure on the optic chiasm caus-
ing visual field defects and 2) lack of normalisation of 
prolactin concentration and reduction of tumour size 
in the control MRI despite the use of the maximally 
tolerated cabergoline dose [3]. In cases where treatment 
with bromocriptine has been initiated and therapeutic 
success has not been achieved, the decision on neu-
rosurgical management should be preceded by using 
cabergoline. So far, no studies have been published that 
compare the effectiveness of tumour volume reduction 
using different dopamine agonists, but in available 
studies, the reduction of prolactin tumour size was 
achieved in 50% of patients treated with bromocriptine 
and in 90% of patients treated with cabergoline [3, 55]. 
The tolerance of therapy and the economic barrier of 
the availability of the medicine remain a separate issue.
Conclusions
MEN1 is a rare disease with a complicated and still 
poorly understood course. The diagnosis and treatment 
of MEN1-related pituitary tumours is an important and 
difficult task for clinicians.
MEN1-related tumours are larger, more aggressive, 
resistant to conventional therapy, and occur in younger 
age groups compared to sporadic tumours. Patients 
with MEN1 syndrome have a reduced life expectancy, 
and the results of treatment of individual components 
of the syndrome (including pituitary tumours) are sig-
nificantly worse than the treatment of similar tumours 
in patients without MEN1 mutations.
The effectiveness of treatment and survival progno-
sis in patients with MEN1 syndrome may be improved 
by using early, evidence-based diagnosis and treatment. 
Patients and their families should remain under the care 
of specialised endocrinological centres experienced in 
the diagnosis and treatment of all components of the 
syndrome and with full diagnostic facilities (genetic 
laboratory, SPECT, SRS, MR), cooperating with an expe-
rienced neurosurgeon, radiologist, and oncologist. Fur-
ther studies investigating early diagnostic markers and 
markers of the response to treatment should be carried 
out. There is also a need to create updated guidelines 
of the diagnosis and treatment to improve the effec-
tiveness of the care of patients with MEN1 mutations. 
Funding
The authors did not receive any specific grant from 
any funding agency in the public, commercial, or 
not-for-profit sector.
Conflicts of interests
The authors declare none.
Author contributions
The first authorship of D.R. and A.G.J. is of equal rank.
References
1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary 
adenomas: a systematic review. Cancer. 2004; 101(3): 613–619, 
doi: 10.1002/cncr.20412, indexed in Pubmed: 15274075.
451





2. Newey PJ, Gorvin CM, Cleland SJ. Mutant prolactin receptor and 
familial hyperprolactinemia. N Engl J Med. 2013; 369(21): 2012–2020, 
doi: 10.1056/NEJMoa1307557, indexed in Pubmed: 24195502.
3. Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Di-
agnosis and treatment of hyperprolactinemia: an Endocrine Society 
clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2): 273–288, 
doi: 10.1210/jc.2010-1692, indexed in Pubmed: 21296991.
4. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: 
a community-based, cross-sectional study in Banbury (Oxfordshire, UK). 
Clin Endocrinol (Oxf). 2010; 72(3): 377–382, doi: 10.1111/j.1365-2265.200
9.03667.x, indexed in Pubmed: 19650784.
5. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adeno-
mas: a cross-sectional study in the province of Liege, Belgium. J Clin 
Endocrinol Metab. 2006; 91(12): 4769–4775, doi:  10.1210/jc.2006-1668, 
indexed in Pubmed: 16968795.
6. Caimari F, Korbonits M. Novel Genetic Causes of Pituitary Adeno-
mas. Clin Cancer Res. 2016; 22(20): 5030–5042, doi: 10.1158/1078-0432.
CCR-16-0452, indexed in Pubmed: 27742789.
7. Marques P, Korbonits M. Genetic Aspects of Pituitary Adenomas. En-
docrinol Metab Clin North Am. 2017; 46(2): 335–374, doi:  10.1016/j.
ecl.2017.01.004, indexed in Pubmed: 28476226.
8. Falchetti A, Marini F, Luzi E, et al. Multiple endocrine neoplasia type 
1 (MEN1): not only inherited endocrine tumors. Genet Med. 2009; 
11(12): 825–835, doi:  10.1097/GIM.0b013e3181be5c97, indexed in 
Pubmed: 19904212.
9. Syro LV, Scheithauer BW, Kovacs K, et al. Pituitary tumors in patients 
with MEN1 syndrome. Clinics (Sao Paulo). 2012; 67(Suppl 1): 43–48, 
doi: 10.6061/clinics/2012(Sup01)09, indexed in Pubmed: 22584705.
10. Underdahl LO, Woolner LB, Black BM. Multiple endocrine adenomas; 
report of 8 cases in which the parathyroids, pituitary and pancre-
atic islets were involved. J Clin Endocrinol Metab. 1953; 13(1): 20–47, 
doi: 10.1210/jcem-13-1-20, indexed in Pubmed: 13022748.
11. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J 
Med. 1954; 16(3): 363–371, doi: 10.1016/0002-9343(54)90353-8, indexed 
in Pubmed: 13138607.
12. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional clon-
ing of the gene for multiple endocrine neoplasia-type 1. Science. 
1997; 276(5311): 404–407, doi: 10.1126/science.276.5311.404, indexed in 
Pubmed: 9103196.
13. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best 
Pract Res Clin Endocrinol Metab. 2010; 24(3): 355–370, doi: 10.1016/j.
beem.2010.07.003, indexed in Pubmed: 20833329.
14. Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical 
practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J 
Clin Endocrinol Metab. 2012; 97(9): 2990–3011, doi: 10.1210/jc.2012-1230, 
indexed in Pubmed: 22723327.
15. Corbetta S, Pizzocaro A, Peracchi M, et al. Multiple endocrine neopla-
sia type 1 in patients with recognized pituitary tumours of different 
types. Clin Endocrinol (Oxf). 1997; 47(5): 507–512, doi: 10.1046/j.1365-2
265.1997.3311122.x, indexed in Pubmed: 9425388.
16. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and 
therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12): 
5658–5671, doi: 10.1210/jcem.86.12.8070, indexed in Pubmed: 11739416.
17. Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary mac-
roadenoma in a 5-year-old: an early expression of multiple endocrine 
neoplasia type 1. J Clin Endocrinol Metab. 2000; 85(12): 4776–4780, 
doi: 10.1210/jcem.85.12.7064, indexed in Pubmed: 11134142.
18. Falchetti A. Genetic screening for multiple endocrine neoplasia 
syndrome type 1 (MEN-1): when and how. F1000 Med Rep. 2010; 2, 
doi: 10.3410/M2-14, indexed in Pubmed: 20948872.
19. Machens A, Schaaf L, Karges W, et al. Age-related penetrance of 
endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): 
a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 
2007; 67(4): 613–622, doi:  10.1111/j.1365-2265.2007.02934.x, indexed in 
Pubmed: 17590169.
20. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 
(MEN1): analysis of 1336 mutations reported in the first decade fol-
lowing identification of the gene. Hum Mutat. 2008; 29(1): 22–32, 
doi: 10.1002/humu.20605, indexed in Pubmed: 17879353.
21. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations 
in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 
1998; 62(2): 232–244, doi: 10.1086/301729, indexed in Pubmed: 9463336.
22. Turner JJO, Leotlela PD, Pannett AAJ, et al. Frequent occurrence of 
an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin 
Endocrinol Metab. 2002; 87(6): 2688–2693, doi: 10.1210/jcem.87.6.8607, 
indexed in Pubmed: 12050235.
23. Starker LF, Akerström T, Long WD, et al. Frequent germ-line muta-
tions of the MEN1, CASR, and HRPT2/CDC73 genes in young patients 
with clinically non-familial primary hyperparathyroidism. Horm 
Cancer. 2012; 3(1–2): 44–51, doi: 10.1007/s12672-011-0100-8, indexed in 
Pubmed: 22187299.
24. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine 
tumor syndromes: advances in molecular pathogenesis, diagnosis, 
management, and controversies. Cancer. 2008; 113(7 Suppl): 1807–1843, 
doi: 10.1002/cncr.23648, indexed in Pubmed: 18798544.
25. Raverot G, Burman P, McCormack A, et al. European Society of Endocri-
nology. European Society of Endocrinology Clinical Practice Guidelines 
for the management of aggressive pituitary tumours and carcinomas. Eur 
J Endocrinol. 2018; 178(1): G1–G24, doi: 10.1530/EJE-17-0796, indexed 
in Pubmed: 29046323.
26. Skalniak A, Sokołowski G, Jabrocka-Hybel A, et al. A novel in-frame dele-
tion in MEN1 (p.Ala416del) causes familial multiple endocrine neoplasia 
type 1 with an aggressive phenotype and unexpected inheritance pat-
tern. Mol Med Rep. 2016; 14(3): 2061–2066, doi: 10.3892/mmr.2016.5462, 
indexed in Pubmed: 27430871.
27. Multiple Endocrine Neoplasia Type 1 (MEN1) Workup: Approach 
Considerations, Laboratory Studies, Imaging Studies. https:/emedicine.
medscape.com/article/126438-workup (February 25, 2019).
28. MEN1 screening protocol (Published January 2017). http://www.edin-
burghdiabetes.com/s/2017-02-01-MEN1-Screening.docx.
29. Drug Safety and Availability — FDA Drug Safety Communica-
tion: FDA evaluating the risk of brain deposits with repeated use of 
gadolinium-based contrast agents for magnetic resonance imaging 
(MRI) (Published July 25, 2015)).  https://www.fda.gov/Drugs/Drug-
Safety/ucm455386.htm (Accessed February 25, 2019.).
30. Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium de-
position within the dentate nucleus and globus pallidus after repeated 
administrations of gadolinium-based contrast agents — current sta-
tus. Neuroradiology. 2016; 58(5): 433–441, doi: 10.1007/s00234-016-1658-1, 
indexed in Pubmed: 26873830.
31. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 
21 years old: a 160-patient cohort study from the Groupe d’étude des 
Tumeurs Endocrines. J Clin Endocrinol Metab. 2015; 100(4): 1568–1577, 
doi: 10.1210/jc.2014-3659, indexed in Pubmed: 25594862.
32. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death 
in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) 
cohort study among 758 patients. World J Surg. 2010; 34(2): 249–255, 
doi: 10.1007/s00268-009-0290-1, indexed in Pubmed: 19949948.
33. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology 
of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(s2): 2–8, 
doi: 10.1111/j.1365-2036.2006.02943.x, indexed in Pubmed: 16700898 .
34. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple en-
docrine neoplasia type 1-related gastrinomas and pancreatic en-
docrine neoplasias. Ann Surg. 2006; 244(1): 61–70, doi:  10.1097/01.
sla.0000218073.77254.62, indexed in Pubmed: 16794390.
35. Norton JA, Fraker DL, Alexander HR, et al. Surgery to Cure the 
Zollinger–Ellison Syndrome. N Engl J Med. 1999; 341(9): 635–644, 
doi: 10.1056/NEJM199908263410902, indexed in Pubmed: 10460814.
36. Waldmann J, López CL, Langer P, et al. Surgery for multiple endo-
crine neoplasia type 1-associated primary hyperparathyroidism. 
Br J Surg. 2010; 97(10): 1528–1534, doi:  10.1002/bjs.7154, indexed in 
Pubmed: 20629112.
37. Schreinemakers JMJ, Pieterman CRC, Scholten A, et al. The opti-
mal surgical treatment for primary hyperparathyroidism in MEN1 
patients: a systematic review. World J Surg. 2011; 35(9): 1993–2005, 
doi: 10.1007/s00268-011-1068-9, indexed in Pubmed: 21713580.
38. Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best 
Pract Res Clin Endocrinol Metab. 2007; 21(1): 87–109, doi: 10.1016/j.
beem.2006.12.004, indexed in Pubmed: 17382267.
39. Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 
(MEN1): data from the France-Belgium MEN1 multicenter study. J Clin 
Endocrinol Metab. 2002; 87(2): 457–465, doi:  10.1210/jcem.87.2.8145, 
indexed in Pubmed: 11836268.
40. Wilson-Hardy classification. NeuroMind.cc.  https://www.neuromind.
cc/tumor/wilson-hardy-classification/ (March 5, 2019).
41. Trouillas J, Labat-Moleur F, Sturm N, et al. Groupe d’études des Tumeurs 
Endocrines. Pituitary tumors and hyperplasia in multiple endocrine 
neoplasia type 1 syndrome (MEN1): a case-control study in a series 
of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 
2008; 32(4): 534–543, doi:  10.1097/PAS.0b013e31815ade45, indexed in 
Pubmed: 18300794.
42. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spec-
trum of manifestations of multiple endocrine neoplasia type 1. Surgery. 
1998; 124(6): 1106–1114, doi: doi:10.1067/msy.1998.93107, indexed in 
Pubmed: 9854591.
43. Horvath A, Stratakis CA. Clinical and molecular genetics of acro-
megaly: MEN1, Carney complex, McCune-Albright syndrome, familial 
acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab 
Disord. 2008; 9(1): 1–11, doi:  10.1007/s11154-007-9066-9, indexed in 
Pubmed: 18200440.
44. Saeger W, Petersenn S, Schöfl C, et al. Emerging Histopathological and 
Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recom-
452





mendation for Future WHO Classification. Endocr Pathol. 2016; 27(2): 
115–122, doi: 10.1007/s12022-016-9419-6, indexed in Pubmed: 26874696.
45. Garby L, Caron P, Claustrat F, et al. GTE Group. Clinical character-
istics and outcome of acromegaly induced by ectopic secretion of 
growth hormone-releasing hormone (GHRH): a French nationwide 
series of 21 cases. J Clin Endocrinol Metab. 2012; 97(6): 2093–2104, 
doi: 10.1210/jc.2011-2930, indexed in Pubmed: 22442262.
46. Saleem TF, Santhanam P, Hamoudeh E, et al. Acromegaly caused by 
growth hormone releasing hormone (GHRH) secreting tumor in 
multiple endocrine neoplasia (MEN-1). W V Med J. 2012; 108(2): 26–30, 
indexed in Pubmed: 22655432.
47. Berger G, Trouillas J, Bloch B, et al. Multihormonal carcinoid 
tumor of the pancreas. Secreting growth hormone-releasing fac-
tor as a cause of acromegaly. Cancer. 1984; 54(10): 2097–2108, 
doi:  10.1002/1097-0142(19841115)54:10<2097::AID-CNCR2820541009>
3.0.CO;2-X, indexed in Pubmed: 6435852.
48. Stelmachowska-Banaś M, Głogowski M, Vasiljevic A, et al. Ectopic 
acromegaly due to growth hormone-releasing hormone secretion 
from bronchial carcinoid causing somatotroph hyperplasia and partial 
pituitary insufficiency. Pol Arch Intern Med. 2019; 129(3): 208–210, 
doi: 10.20452/pamw.4413, indexed in Pubmed: 30608060.
49. Bolanowski M, Schopohl J, Marciniak M, et al. Acromegaly due to 
GHRH-secreting large bronchial carcinoid. Complete recovery follow-
ing tumor surgery. Exp Clin Endocrinol Diabetes. 2002; 110(4): 188–192, 
doi: 10.1055/s-2002-32151, indexed in Pubmed: 12058343.
50. Benito M, Asa SL, Livolsi VA, et al. Gonadotroph tumor associ-
ated with multiple endocrine neoplasia type 1. J Clin Endocrinol 
Metab. 2005; 90(1): 570–574, doi:  10.1210/jc.2004-1373, indexed in 
Pubmed: 15522929.
51. Gordon MV, Varma D, McLean CA, et al. Metastatic prolactinoma pre-
senting as a cervical spinal cord tumour in multiple endocrine neoplasia 
type one (MEN-1). Clin Endocrinol (Oxf). 2007; 66(1): 150–152, doi: 10.1
111/j.1365-2265.2006.02697.x, indexed in Pubmed: 17201817.
52. Scheithauer BW, Kovacs K, Nose V, et al. Multiple endocrine neoplasia 
type 1-associated thyrotropin-producing pituitary carcinoma: report 
of a probable de novo example. Hum Pathol. 2009; 40(2): 270–278, 
doi: 10.1016/j.humpath.2008.06.013, indexed in Pubmed: 18755492.
53. Gilis-Januszewska A, Wilusz M, Pantofliński J, et al. Temozolomide 
therapy for aggressive pituitary Crooke’s cell corticotropinoma causing 
Cushing’s Disease - a case report with literature review. Endokrynol 
Pol. 2018; 69(3): 306–312, doi:  10.5603/EP.a2018.0011, indexed in 
Pubmed: 29319131.
54. de Laat JM, Dekkers OM, Pieterman CRC, et al. Long-Term Natural 
Course of Pituitary Tumors in Patients With MEN1: Results From the 
DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab. 2015; 100(9): 
3288–3296, doi: 10.1210/JC.2015-2015, indexed in Pubmed: 26126205.
55. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary 
therapy for prolactin-secreting macroadenomas: results of a prospec-
tive multicenter study. J Clin Endocrinol Metab. 1985; 60(4): 698–705, 
doi: 10.1210/jcem-60-4-698, indexed in Pubmed: 3882737.
